Pliant Therapeutics Inc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full U.S. share.
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, bexotegrast (PLN-74809), is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. Its second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs targeting muscular dystrophies. It is also developing PLN-101095 an oral, dual inhibitor of αvß8 and αvß1 integrins for the treatment of solid tumors. Its clinical programs also include PLN-101325, an allosteric agonistic monoclonal antibody against α7β1 for treatment of muscular dystrophies.
Buy US stocks in Australia starting with PLRX. Open an account and start investing today!
Ready to start your investing journey with Stake?Open an account
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in PLRX
Invest in PLRX
Buy PLRX from US$3 brokerage
Invest in 6,000+ U.S. stocks and ETFs
Own a slice of PLRX from only US$10 with fractional shares